Core Insights - IBA has signed a contract with Telix Pharmaceuticals for the initial order of four Cyclone KIUBE cyclotrons to be installed at RLS Radiopharmacies in the U.S. [1][2] - This investment aims to enhance Telix's U.S. manufacturing capabilities, ensuring in-house production of critical isotopes and radiopharmaceuticals for cancer care [2][5] Company Overview - IBA is a leader in particle accelerator technology and radiopharmaceutical production, employing approximately 2,100 people globally [5][6] - Telix Pharmaceuticals focuses on developing therapeutic and diagnostic radiopharmaceuticals, with operations in multiple countries including the U.S., U.K., and Japan [6] Technological Advancements - The Cyclone KIUBE 180 was chosen for its high-current capacity and reliability, equipped with the QUANTM Irradiation System (QIS) for compliant production of key radio-metals [3] - This collaboration aims to improve the production efficiency of high-demand isotopes, reducing reliance on external suppliers [3][4] Strategic Goals - The partnership between IBA and Telix is designed to strengthen supply chain resilience and improve patient outcomes by ensuring reliable access to diagnostic tools [2][5] - The agreement supports IBA's growth in the RadioPharma Solutions market, reinforcing its leading position [2]
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.